Healthcare / Medical DevicesSwiss
$74.60
-3.20 (-4.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $9.3M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$927M
P/E
111.3x
↑EV/EBITDA
23.0x
↑ROE
3.0%
↑Gross Margin
75.9%
↑Debt/Equity
0.57
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.8%
FCF CAGR
—
FCF margin
3.5%
FCF / Net income
1.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $269.3M · net income $8.3M · FCF $9.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $269.3M | $269.3M | $224.8M | $212.0M | $182.8M |
| Net Income | $8.3M | $8.3M | $3.5M | $619000.00 | $-5.8M |
| EBITDA | $45.7M | $45.7M | $30.2M | $25.4M | $11.7M |
| EPS | 0.67 | 0.67 | 0.28 | 0.05 | -0.49 |
| Gross Margin | 75.9% | 75.9% | 79.5% | 79.0% | 81.8% |
| Operating Margin | 0.7% | 0.7% | 3.2% | 3.9% | -1.0% |
| Net Margin | 3.1% | 3.1% | 1.6% | 0.3% | -3.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.57 | 0.57 | 0.45 | 0.11 | 0.12 |
| Current Ratio | 2.21 | 2.21 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $9.3M | $9.3M | $21.0M | $1.2M | $-22.7M |
| Returns | |||||
| ROE | 3.0% | 3.0% | 1.3% | 0.2% | -2.4% |
| Valuation | |||||
| P/E | 111.34 | 111.34 | 206.07 | 1564.00 | — |
| EV/EBITDA | 23.04 | 23.04 | 23.12 | 37.87 | 83.52 |
| P/B | 3.37 | 3.37 | 2.65 | 3.76 | 4.08 |
| Growth & Yield | |||||
| Revenue Growth | 19.8% | 19.8% | 6.0% | 16.0% | — |
| EPS Growth | 139.3% | 139.3% | 460.0% | 110.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
114.6%
EPS terminal req.
$6.62
Spread vs growth
24.7%
5Y implied EPS CAGR
64.3%
EPS terminal req.
$8.01
Spread vs growth
75.0%
10Y implied EPS CAGR
34.4%
EPS terminal req.
$12.90
Spread vs growth
104.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.5%
Start / end P/E
278.9x → 111.3x
EPS bridge
0.28 → 0.67
Residual
-83.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.